In this discussion hosted by the Milken Insitute, the funding and the creation of incentives to enable medical research breakthroughs are discussed. With panel participant Ruxandra Draghia-Akli (Director, Health Directorate, Directorate-General for Research and Innovation, European Commission), Gary Nabel (Chief Scientific Officer and Senior Vice President, Sanofi), Tim Peakman (Deputy CEO, UK Biobank, and CEO, UK Biocentre) and Sir Mark Walport (Chief Scientific Advisor, UK Government). Also moderator Margaret Anderson (Executive Director, FasterCures).
In recent decades, investment in biomedical research has transformed scientific discoveries into medicines, vaccines, diagnostics and devices that improve and save people’s lives. Yet the flow of funding, both public and private, has slowed due to a retreat from risk, regulatory hurdles and other issues. Nevertheless, a tremendous range of promising, innovative research is underway, backed by industry and public-private partnerships, and a growing number of leaders are recognizing the value of such investments.
This Milken Institute panel discuss the process and payoffs of funding biomedical inquiry and what can be done to revitalize and sustain it. Where are the best opportunities for returns – medical, financial and societal – in the coming years? Take, for instance, the huge investments in cancer research, cardiovascular treatments and polio eradication. What kind of results have we seen? The assembled experts will also explore bioscience’s impact on the broader economy, including productivity, jobs and reduced absenteeism.
The Milken institute: “Our mission is to improve lives around the world by advancing innovative economic and policy solutions that create jobs, widen access to capital and enhance health”.